Oruka Therapeutics, Inc. $ORKA Position Trimmed by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC decreased its position in Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 26.2% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 74,806 shares of the company’s stock after selling 26,605 shares during the quarter. Oruka Therapeutics accounts for 1.2% of Moody Aldrich Partners LLC’s portfolio, making the stock its 16th biggest holding. Moody Aldrich Partners LLC owned approximately 0.11% of Oruka Therapeutics worth $6,231,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Sterling Capital Management LLC boosted its position in shares of Oruka Therapeutics by 839.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,662 shares of the company’s stock valued at $138,000 after acquiring an additional 1,485 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Oruka Therapeutics by 201.6% in the third quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock valued at $31,000 after purchasing an additional 250 shares in the last quarter. Engineers Gate Manager LP purchased a new position in shares of Oruka Therapeutics in the second quarter valued at $350,000. Arizona State Retirement System increased its position in Oruka Therapeutics by 45.0% in the second quarter. Arizona State Retirement System now owns 8,671 shares of the company’s stock worth $825,000 after purchasing an additional 2,691 shares during the last quarter. Finally, Nykredit A S bought a new stake in Oruka Therapeutics in the second quarter worth $29,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $95.97 on Thursday. Oruka Therapeutics, Inc. has a 1-year low of $25.23 and a 1-year high of $115.51. The firm has a market capitalization of $6.35 billion, a P/E ratio of -47.28 and a beta of -0.37. The company’s 50-day moving average is $88.89 and its 200 day moving average is $68.23.

Oruka Therapeutics (NASDAQ:ORKA) last announced its quarterly earnings data on Monday, August 10th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.04). Research analysts anticipate that Oruka Therapeutics, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Oruka Therapeutics

In other news, CEO Lawrence Klein sold 25,000 shares of the business’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $83.62, for a total transaction of $2,090,500.00. Following the completion of the sale, the chief executive officer directly owned 923,128 shares of the company’s stock, valued at approximately $77,191,963.36. The trade was a 2.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Arjun Agarwal sold 9,999 shares of the business’s stock in a transaction dated Monday, October 12th. The shares were sold at an average price of $80.60, for a total transaction of $805,919.40. Following the completion of the sale, the senior vice president directly owned 14,219 shares of the company’s stock, valued at approximately $1,146,051.40. This trade represents a 41.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 154,950 shares of company stock worth $14,102,680. 23.49% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

ORKA has been the subject of several research reports. UBS Group increased their price objective on shares of Oruka Therapeutics from $100.00 to $130.00 and gave the company a “buy” rating in a research report on Wednesday, July 1st. Wedbush reissued an “outperform” rating and issued a $165.00 price objective on shares of Oruka Therapeutics in a research note on Tuesday. Mizuho set a $120.00 target price on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Piper Sandler restated an “overweight” rating on shares of Oruka Therapeutics in a research report on Wednesday, October 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research report on Tuesday, October 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $133.00.

About Oruka Therapeutics

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.